Combination Therapy to Prevent Resistance to Anti-PD-1 Treatment in Metastatic Ovarian Cancer Patients

Inclusion Criteria

• Women aged 18 or older with advanced ovarian cancer that has not responded to platinum-based chemotherapy.
• Must have cancer that can be measured by scans and has progressed after standard treatment.
• Must be willing to provide written consent and undergo necessary medical evaluations.
• Must have recovered from any recent surgery, radiation, or chemotherapy.
• Must not have any active infections requiring antibiotics, except for simple urinary tract infections.
• Must have stopped any hormonal therapy for the cancer at least one week before joining the study.
• Must have stopped any other cancer treatments at least four weeks before joining the study.
• Must have at least one measurable tumor.
• Must agree to provide tumor samples for research purposes.
• Must have a performance status score of 2 or less, indicating they are able to carry out light work.
• Must have adequate organ function as shown by specific blood tests.
• Women of childbearing potential must use effective contraception during the study and for 180 days after the last dose.

Exclusion Criteria

• Previous treatment with certain immune therapies like nivolumab or other similar drugs.
• Any condition that might interfere with the study or affect safety assessments.
• Severe allergic reactions to unknown allergens or study drug components.
• Active or recent autoimmune diseases, except for certain stable conditions.
• Participation in another clinical study, unless it is non-interventional.
• Recent use of other cancer treatments not specified in the inclusion criteria.
• Unresolved side effects from previous cancer treatments.
• Use of immunosuppressive medication within 14 days before starting the study, with some exceptions.
• History of primary immunodeficiency, organ transplant, or tuberculosis.
• Active infections like hepatitis B, C, or HIV.
• Recent receipt of live vaccines.
• Pregnant or breastfeeding women.
• Recent major surgery or still recovering from surgery.
• Other invasive cancers within the last two years, except for certain non-invasive cancers.
• Uncontrolled illnesses or conditions that could interfere with the study or increase risks.